A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 59-68

  Mainou Fowler, Tryfonia ^a   Overman, Lynn Marie ^a   Dignum, Helen ^a   Wood, Katrina ^a   Crosier, Stephen ^a   Angus, Brian ^a   Proctor, Stephen John ^a   Anderson, John J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

bcl 2; Diffuse large B cell lymphoma; IAP survivin; Monoclonal antibody; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F2 9C3; PREDNISONE; PROTEIN BCL 2; RECOMBINANT PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MITOSIS SPINDLE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

EID: 38749101546     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.59     Document Type: Article

References (44)

1. Jin Z and El-Deiry WS: Overview of cell death signalling pathways. Cancer Biol Ther 4: 139-163, 2005.
2. Rudin CM and Thompson CB: Apoptosis and disease: Regulation and clinical relevance of programmed cell death. Annu Rev Med 48: 267-281, 1997.
3. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
4. Tsujimoto Y, Cossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
5. Jaattela M: Escaping cell death: Survival proteins in cancer. Exp Cell Res 248: 30-43, 1999.
6. Sup SJ, Alemany CA, Pohlman B, et al: Expression of bcl-2 in classical Hodgkin's lymphoma: An independent predictor of poor outcome. J Clin Oncol 23: 3773-3779, 2005.
7. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90: 244-251, 1997.
8. Barrans SL, Carter I, Owen RG, et al: Germinal centre phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99: 1136-1143, 2002.
9. Colomo L, Lopez-Guillermo A, Perales M, et al: Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101: 78-84, 2003.
10. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
11. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Gene Dev 13: 239-252, 1999.
12. Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5: 447-452, 2003.
13. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
14. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by fas (CD95), bax, caspases, and anti-cancer drugs. Cancer Res 58: 5315-5320, 1998.
15. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Diff 9: 1334-1342, 2002.
16. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-△Ex3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102, 1999.
17. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T and Inuzuka M: Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 314: 902-907, 2004.
18. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
19. Fukuda S and Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5: 1087-1098, 2006.
20. Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett 244: 164-171, 2006.
21. Adida C, Haioun C, Gaulard P, et al: Prognostic significance of survivin expression in diffuse large B-cell lymphoma. Blood 96: 1921-1925, 2000.
22. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861, 2007.
23. Project TIN-HsLPF: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994, 1993.
24. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
25. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002.
26. Muris JJF, Meijer CJLM, Vos W, vanKrieken JHJM, Jiwa NM, Ossenkoppele GJ and Oudejans JJ: Immunohistochemical profiling based on bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208: 714-723, 2006.
27. Cameron DA, White JM, Proctor SJ, et al: CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Eur J Cancer 33: 1195-1201, 1997.
28. Lodge AJ, Anderson JJ, Ng SW, Fenwick F, Steward M, Haugk B, Horne CHW and Angus B: Expression of topoisomerase IIIa in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody. Br J Cancer 83: 498-505, 2000.
29. Detre S, Saclani Jotti G and Dowsett M: A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878, 1995.
30. Jaffe ES, Harris NL, Diebold J and Muller-Hermelink HK: World Health Organization classification of lymphomas: a work in progress. Ann Oncol 9: S25-S30, 1998.
31. Lens SMA, Vader G and Medema RH: The case for survivin as mitotic regulator. Curr Opin Cell Biol 18: 616-622, 2006.
32. Spaulding B, Pan D, Ghadersohi A, et al: Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology 49: 622-633, 2006.
33. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216, 2005.
34. Hirokawa N: Microtubule organisation and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol 6: 74-71, 1994.
35. Li F, Yang J, Ramnath N, Javle MM and Tan D: Nuclear or cytoplasmic expression of survivin: What is the significance? Int J Cancer 114: 509-512, 2005.
36. Rodriquez JA, Span SW, Ferreira CGM, Kruyt FAE and Giaccone G: CRM-1 mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res 275: 44-53, 2002.
37. Kuttler F, Valnet-Rabier M-B, Angonin R, et al: Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16: 726-735, 2002.
38. Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18: 609-615, 2006.
39. Martinez A, Bellosillo B, Bosch F, et al: Nuclear survivin expression in Mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164: 501-510, 2004.
40. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87: 265-272, 1996.
41. Lossos IS and Morgensztern D: Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24: 995-1007, 2006.
42. Manion MK and Hockenberry DM: Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2: S105-S114, 2003.
43. Olie RA, Simoes-Wust P, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
44. Ansell SM, Arendt BK, Grote DM, et al: Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18: 616-623, 2004.